6318-42-9

Upstream product

• 590-28-3 potassium cyanate 
• 6230-11-1 O-Methyltyrosine 
• 5349-42-8 5-(4-methoxybenzylidene)imidazolidine-2,4-dione 
• 7440-02-0 nickel 
• 95474-45-6 5-p-methoxybenzylidene-2-thiohydantoin 
• 120697-20-3 5-(4-methoxy-benzylidene)-imidazolidine-2,4-dione 
• 5703-26-4 4-Methoxyphenylacetaldehyde 

Downstream Products

• 96409-59-5 p-methoxybenzyl-1-methylhydantoin 
• 6230-11-1 O-Methyltyrosine 
• 70601-62-6 (D)-N-acetyl-4-methoxy-phenylalanine 
• 39878-65-4 (R)-β-(4-methoxyphenyl)alanine 
• 7635-29-2 O-methyl tyrosine 

Relevant academic research and scientific papers

3, 5-disubstituted hydantoin compound as well as preparation method and application thereof

The invention provides a 3, 5-disubstituted hydantoin compound as well as a preparation method and an application thereof. The structure of the compound is shown in formula I in the description. The application of the 3, 5-disubstituted hydantoin compound shown in the formula I or solvates, hydrates or salts of the compound in preparation of medicines for treating Alzheimer's disease, vascular dementia and other dementia diseases with memory impairment also belongs to the protection scope. Animal experiments prove that the compound has the effect of saving memory of animal models, has high safety, does not have mutagenicity, can stay in blood for several hours after oral administration and intravenous injection, and can enter the brain.

Process for the preparation of D1-β-aryl amino acids

The invention relates to a process for the preparation of DL-β-aryl-amino acids of the general Formula STR1 wherein R, R1 and R2 stand for hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, nitro or C1-4 dialkylamino; whereby in the case of monosubstituted derivatives R and R1 are hydrogen and R2 has the same meaning as stated above and can be attached to position 2, 3 or 4 related to the methylene group; in the case of disubstituted derivatives R is hydrogen and R1 and R2 have the same meaning as stated above and are attached to positions 2,3; 2,4; 2,5; 2,6; 3,4 or 3,5 related to the methylene group; in the case of trisubstituted derivatives R, R1 and R2 have the same meaning as stated above and are attached to positions 2,3,4; 2,3,5; 2,3,6; 3,4,5 or 3,4,6 related to the methylene group.

Octapeptides and methods for their production

New octapeptides having the formula Prot Grp-R-Trp-Ser-Tyr-R2 -Leu-Arg-Pro-R3 ; salts thereof; wherein R is Gln, Gln (bzl), His (bzl), Ser (bzl), Pro, Leu, Tyr (bzl), Ile, Cys (bzl) or Phe, R2 is D-Phe, D-Ala, D-Leu, D-Trp, D-Tyr, D-Tyr (Me), D-Ser, D-Met, D-Arg, D-Val, D-His, D-Gln, D-Phs, D-Thr, D-Pro, D-Me5 Phe or D-Asn and R3 is NH2, NH(lower alkyl), N-(lower alkyl)2, NH-benzyl, NHCH2 CH2 N-(lower alkyl)2 or NH-CH2 CH2 SO2 NH-benzyl; methods for their production; certain peptide intermediates and their salts used in the production thereof; and the use of said octapeptides as luteinizing hormone releasing factor antagonists.